Study of Multiple Indications in Direct-to-Consumer Television Advertisements

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
Supporting Statement Part A - Multiple Indications Study 2021.docx	Supporting Statement B	Uploaded 2021-02-09	Repair queued
Supporting Statement Part A - Multiple Indications Study 2021.docx	Supporting Statement A	Uploaded 2021-02-09	Repair queued

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
245718	Main Study 1 and 2	Other-Questionnaire	New
245717	Main Study 1 and 2 Screener	Other-Consent Form	New
245716	Pretest 1 and 2	Other-Questionnaire	New
245715	Pretest 1 and 2 Screener	Other-Consent Form	New

ICR Details

OMB Control No: 0910-0897	ICR Reference No: 202102-0910-001
Status: Historical Active	Previous ICR Reference No:
Agency/Subagency: HHS/FDA	Agency Tracking No: CDER
Title: Study of Multiple Indications in Direct-to-Consumer Television Advertisements
Type of Information Collection: New collection (Request for a new OMB Control Number)	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved with change	Conclusion Date: 05/05/2021
Retrieve Notice of Action (NOA)	Date Received in OIRA: 03/04/2021
Terms of Clearance: At this time, approval is only granted for the pre-tests. Any substantive changes to the documents or methodology as a result of the pretests must be submitted as revisions; non-substantive updates can be made through a change request.

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	05/31/2024	36 Months From Approved
Responses	3,052	0	0
Time Burden (Hours)	508	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: The purpose of this study is to collect data on consumer understanding of multiple prescription drug indications in direct-to-consumer television advertisements. We plan to conduct two pretests (N=60 each) and two main studies (N=402 in Study 1; N=402 in Study 2) with US adults. Pretests and main studies will be 20 minutes and administered via Internet panel. In each study, we will vary the indications presented (one indication, one indication plus a similar indication, one indication plus a dissimilar indication) in a television ad for a fictitious prescription drug for diabetic neuropathy (pretest 1 and Study 1) or rheumatoid arthritis (pretest 2 and Study 2). Participants will view the television ad and answer questions about it.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	85 FR 40296	07/06/2020
30-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 12692	03/04/2021
Did the Agency receive public comments on this ICR? Yes

---

Number of Information Collection (IC) in this ICR: 4

table that charts list of burden

IC Title	Form No.	Form Name
Main Study 1 and 2
Main Study 1 and 2 Screener
Pretest 1 and 2
Pretest 1 and 2 Screener

---

ICR Summary of Burden

table that charts list of burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	3,052	0	0	3,052	0	0
Annual Time Burden (Hours)	508	0	0	508	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to: Miscellaneous Actions

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: This is a new data collection.

---

Annual Cost to Federal Government: $517,941

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? No

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 03/04/2021

---